Drug Search Results
More Filters [+]

B-267

Alternative Names: B-267, B267
Latest Update: 2023-08-15
Latest Update Note: PubMed Publication

Product Description

B-267 is being developed by FutureGen for the treatment of solid tumors. (Sourced from: http://www.futuregenbiopharm.com/#/product/pipeline)

Mechanisms of Action: TIGIT Inhibitor

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: FutureGen
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for B-267

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events